Innovating Works

AOUP

Desconocido
LIVERAIM: A Biomarker Based Platform for Early Diagnosis of Chronic Liver Disease to Enable Personalized Thera... AZIENDA OSPEDALE UNIVERSITA PADOVA participó en un HORIZON EUROPE: HORIZON-JU-IHI-2022-03-single-stage Liver cirrhosis and liver cancer are common and responsible for high morbidity, impaired quality of life, major costs for healthcare systems...
2023-11-27 - 2030-02-28 | Financiado
LiverScreen: Screening for liver fibrosis population based study across European countries AZIENDA OSPEDALE UNIVERSITA PADOVA participó en un H2020: H2020-SC1-BHC-2018-2020 Liver cirrhosis is a very common and severe chronic disease, responsible for high morbidity, impaired quality of life, major healthcare cost...
2019-12-12 - 2025-06-30 | Financiado
3TR: Identification of the Molecular Mechanisms of non response to Treatments Relapses and Remission in... AZIENDA OSPEDALE UNIVERSITA PADOVA participó en un H2020: H2020-JTI-IMI2-2018-14-two-stage 3TR is a transdisciplinary consortium made of experts in all areas of medicine, basic sciences and bioinformatics from academic institutions...
2019-08-22 - 2026-08-31 | Financiado
ARISE: African Research and Innovative Initiative for Sickle cell Education Improving Research Capacity fo... AZIENDA OSPEDALE UNIVERSITA PADOVA participó en un H2020: H2020-MSCA-RISE-2018 The Overarching Objective for this consortium is to establish an inter-agency and multidisciplinary staff exchange programme between researc...
2018-10-26 - 2024-10-31 | Financiado
LIVERHOPE: SIMVASTATIN AND RIFAXIMIN AS NEW THERAPY FOR PATIENTS WITH DECOMPENSATED CIRRHOSIS AZIENDA OSPEDALE UNIVERSITA PADOVA participó en un H2020: H2020-SC1-2016-2017 Liver cirrhosis is a very common chronic disease and one of the leading causes of death in European. Moreover, cirrhosis has a marked impact...
2016-12-09 - 2023-02-28 | Financiado
ChiLTERN: Children s Liver Tumour European Research Network AZIENDA OSPEDALE UNIVERSITA PADOVA participó en un H2020: H2020-PHC-2014-2015 Liver cancer in the paediatric population is rare with an incidence approximately 1-1.5 per million population. The commonest tumour seen in...
2015-12-07 - 2021-12-31 | Financiado
CARBALIVE: Clinical evaluation of carbons of controlled porosity as a new therapeutic for the treatment of live... AZIENDA OSPEDALE UNIVERSITA PADOVA participó en un H2020: H2020-PHC-2014-2015 Chronic liver disease affects about 29-million Europeans accounting for about 170,000 deaths at a cost of around €15.8bn. This chronic non-c...
2015-04-07 - 2021-01-31 | Financiado
ARISE: Aortic Valve Replacement using Individualised Regenerative Allografts Bridging the Therapeutic Gap AZIENDA OSPEDALE UNIVERSITA PADOVA participó en un H2020: H2020-PHC-2014-2015 65,000 aortic valve replacements (AVR) are performed in Europe each year to treat acquired and congenital aortic valve diseases. In affected...
2014-12-01 - 2019-03-31 | Financiado
TRANSLINK: Defining the role of xeno directed and autoimmune events in patients receiving animal derived biopro... AZIENDA OSPEDALE UNIVERSITA PADOVA tramitó un FP7: TRANSLINK is a project devoted to assessing the mid-to long-term risk factors and improve the outcome of animal (bovine/porcine)-derived Bio...
Financiado
GRIP: Global Research in Paediatrics AZIENDA OSPEDALE UNIVERSITA PADOVA tramitó un FP7: Paediatric drugs (PD) lack appropriate testing. Most drugs have inadequate information about dosing regimen, dose adjustment and how to admi...
Financiado
SOS: Safety Of non Steroidal anti inflammatory drugs AZIENDA OSPEDALE UNIVERSITA PADOVA participó en un FP7: The Safety Of non-Steroidal anti-inflammatory drugs (SOS) proposal aims to assess the relative cardiovascular (CVD) and gastrointestinal (GI...
Financiado
ESPOIR: European clinical study for the application of regenerative heart valves AZIENDA OSPEDALE UNIVERSITA PADOVA participó en un FP7: Acquired and congenital heart disease can necessitate heart valve replacement. However, current heart valve substitutes are not considered i...
Financiado
EPOC: European Paediatric Oncology Off Patent Medicines Consortium AZIENDA OSPEDALE UNIVERSITA PADOVA participó en un FP7: Cancer chemotherapy has a key role in the successful treatment of a number of childhood cancers. Nevertheless, at least 20% of patients are...
Financiado
DEEP: DEferiprone Evaluation in Paediatrics AZIENDA OSPEDALE UNIVERSITA PADOVA participó en un FP7: β-thalassaemia major is one of the most severe forms of chronic congenital anaemia. The recommended treatment consists in regular blood tran...
Financiado
RESPECT: Relating Expectations and needs to Participation and Empowerment of children in Clinical Trials AZIENDA OSPEDALE UNIVERSITA PADOVA participó en un FP7: There are two objectives for this project, firstly to clarify the expectations and needs of children and their families who have participate...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.